Related Experiment Video
Updated: Aug 10, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Therapy of NAFLD: insulin sensitizing agents
Stephen H Caldwell1, Curtis K Argo, Abdullah M S Al-Osaimi
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-0708, USA. shc5c@virginia.edu
Journal of Clinical Gastroenterology
|March 17, 2006
Summary
Insulin-sensitizing agents like thiazolidinediones and metformin show promise for treating nonalcoholic fatty liver disease (NAFLD). While both improve liver health, thiazolidinediones cause weight gain, and metformin offers more variable histological improvement.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Insulin resistance is a key factor in nonalcoholic fatty liver disease (NAFLD) pathophysiology.
- Nonalcoholic steatohepatitis (NASH) represents a more severe form of NAFLD requiring effective treatments.
- Insulin-sensitizing agents are crucial for managing NAFLD, particularly NASH.
Purpose of the Study:
- To review the literature on thiazolidinediones and metformin for NAFLD treatment.
- To compare the efficacy and side effects of these two insulin-sensitizing agents.
- To assess their potential role in NAFLD management strategies.
Main Methods:
- Literature review of studies involving thiazolidinediones (PPAR-gamma agonists) and metformin in NAFLD patients.
- Analysis of reported effects on hepatic fat, cellular injury, biochemical markers, and histology.
- Evaluation of associated side effects such as weight gain.
Main Results:
- Thiazolidinediones decreased hepatic fat and cellular injury but were linked to increased peripheral fat and weight gain.
- Metformin improved biochemical markers without causing weight gain, but histological improvements were variable.
- Neither agent is FDA-approved for NAFLD, but studies indicate therapeutic potential.
Conclusions:
- Insulin-sensitizing agents hold significant promise for NAFLD and NASH treatment.
- Thiazolidinediones and metformin offer distinct profiles of benefits and drawbacks.
- Further research and selected patient application may integrate these agents into NAFLD management.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...